life scienc tool diagnost
ep exce consensu one-tim item
algn ep beat forecast larg higher
expect gain straumann lawsuit vs estimate
line item lower ep
reflect beat off-set weaker experi america
china well increas advertis spend partial off-set price
increas enhanc manufactur product lower
tp ebitda lower outlook
volum disappoint revenu actual ahead plan
itero growth vs estimate off-set weaker invisalign
case volume vs estimate drop asp roughli line
view reflect fx mix shift albeit deterior america
asp well estimate america volume plan
growth apac reflect note
weak china emea elus teen segment came
also expect vs estimate oper margin rose
bp stmn litig partial off-set mix fx invest
flow million fund million capital-expenditure million
share repurchas remain debt free million cash
share retrench algn recent quarter admittedli
disappoint clear align case volum fell well short expect
tougher consum environ china heighten competit
 america dynam seemingli evolv quicker expect
 america weak appear driven ramp direct-to-
consum dtc offer associ advertis spend
emphas reinvigor advertis campaign expand brand
awar may provid off-set albeit increment cost risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
manufactur system clear align
therapi intra-or scanner cad/cam digit servic use
dentistri orthodont dental record storag
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
price jul rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
figur clear align case shipment patient type volum
figur doctor train geograph segment
compani mention price
